Safety and effectiveness of selective retina therapy combined with anti-VEGF therapy for macular edema

Safety and effectiveness of selective retina therapy combined with anti-VEGF therapy for macular edema - SRT combined with anti-VEGF therapy for macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028347

Enrollment

Registered

2017-09-30

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

branch retinal vein occlusion, central retinal vein occlusion, diabetic macular edema

Interventions

Anti-VEGF alone group Combined Anti-VEGF and SRT group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with macular edema caused subjective symptoms such as central scotoma, metamorphopsia and central visual loss

Exclusion criteria

Exclusion criteria: ophthalmic exclusion criteria: patients who had inflammation within the eye systemic exclusion criteria: people who had systemic inflammatory disease, hemorrhagic diathesis or anticoagulant therapy, untreated hypertension or diabetes mellitus. peple who is pregnant or at risk of becoming pregnant.

Design outcomes

Primary

Measure	Time frame
change of central macular thickness at one-year follow up period	—

Secondary

Measure	Time frame
Number of intravitreal anti-VEGF for 1 year follow-up change of best corrected visual acuity and fluorescein angiography at one-year follow up period	—

Countries

Japan

Contacts

Public ContactManabu Yamamoto

Osaka City University, Graduate School of Medicine, Department of Ophthalmology and Visual sciences Ophthalmology

manabun@msic.med.osaka-cu.ac.jp06-6645-3867

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026